iOrganBio, an innovator in intelligent cell manufacturing that redefines how human cells are engineered and produced at scale, announced today the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang brings expertise in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders, with over 140 publications in top journals such as Nature, Science, Nature Neuroscience, and Nature Metabolism.
Dr. Pang is the Henry Rutgers Professor of NeuroMetabolism and Professor of Neuroscience and Cell Biology at Rutgers Robert Wood Johnson Medical School, and Director of the Center for NeuroMetabolism at Rutgers Health. His addition to the advisory board comes as the field moves toward more human-relevant, non-animal systems, known as New Approach Methodologies (NAMs), which are gaining traction for FDA-aligned research and therapeutic development.
The appointment underscores iOrganBio's commitment to advancing its CellForge™ platform, an AI-powered system for consistent, scalable manufacturing of cells and organoids. The platform uses AI and automation to guide cell development, making real-time adjustments to produce cells with defined biological profiles. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver the accuracy and efficiency needed to accelerate disease modeling, regenerative medicine, and drug development.
For the pharmaceutical and biotechnology industries, the move toward human-relevant models is critical. Traditional animal testing often fails to predict human responses, leading to costly late-stage drug failures. iOrganBio's technology offers a potential solution by enabling the production of human cells and organoids that more closely mimic human biology. Dr. Pang's expertise in neuron biology and neuropsychiatric disorders could help refine these models for studying conditions like autism, schizophrenia, and metabolic diseases, which are notoriously difficult to replicate in animals.
For researchers, this development means access to more reliable and scalable human cell sources. iOrganBio's platform could reduce reliance on primary human tissues, which are often scarce and variable, and provide consistent cell batches for high-throughput screening. The company's focus on intelligent manufacturing also positions it to support cell therapy development, where quality and reproducibility are paramount.
To view the full announcement, including downloadable images, bios, and more, click here.
iOrganBio is transforming human cell production with its CellForge platform, applying engineering precision to biology. By integrating AI and automation, the company aims to turn scientific ideas into breakthroughs, accelerating progress in disease modeling, regenerative medicine, and drug development. For more information, visit iOrgan.Bio or follow on LinkedIn.
